Somaxon Pharmaceuticals, Inc. announces initial public offering

Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. All of the shares of common stock are being offered by the company. Somaxon has granted to the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price to cover over-allotments, if any.

The shares will be quoted on the Nasdaq National Market under the symbol “SOMX.”

Morgan Stanley & Co. Incorporated acted as the sole book-runner and lead manager, J.P. Morgan Securities Inc. acted as co-lead manager, and Piper Jaffray & Co. and Thomas Weisel Partners LLC acted as co-managers of the offering.

A copy of the final prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing prospectus@morganstanley.com, or by contacting the prospectus department at Morgan Stanley & Co. Incorporated, 1585 Broadway, New York, NY 10036, telephone (212) 761-6775.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on December 14, 2005. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Somaxon Pharmaceuticals
Headquartered in San Diego, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon’s lead product candidate, SILENOR™, is in Phase III clinical trials for the treatment of insomnia.